Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases.
Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1.
The company also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases.
It has strategic collaboration and license agreements with Nationwide Children's Hospital; The Research Institute at Nationwide Children's Hospital; REGENXBIO Inc.; and Asklepios Biopharmaceutical, Inc. The company was formerly known as BioLife Cell Bank, Inc. and changed its name to AveXis, Inc. in January 2014.
AveXis, Inc. was founded in 2010 and is headquartered in Bannockburn, Illinois.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 31, 18 | -6.20 Decreased by -479.44% | -3.32 Decreased by -86.75% |
| Dec 31, 17 | -2.55 Decreased by -177.17% | -1.64 Decreased by -55.49% |
| Sep 30, 17 | -1.52 Decreased by -74.71% | -1.54 Increased by +1.30% |
| Jun 30, 17 | -2.07 Decreased by -204.41% | -1.05 Decreased by -97.14% |
| Mar 31, 17 | -1.07 | -0.95 Decreased by -12.63% |
| Dec 31, 16 | -0.92 | -0.80 Decreased by -15.00% |
| Sep 30, 16 | -0.87 | -0.69 Decreased by -26.09% |
| Jun 30, 16 | -0.68 | -0.78 Increased by +12.82% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 18 | 0.00 Decreased by N/A% | -222.10 M Decreased by -647.34% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 17 | 0.00 Decreased by N/A% | -81.67 M Decreased by -221.83% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 17 | 0.00 Decreased by N/A% | -48.64 M Decreased by -130.71% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 17 | 0.00 Decreased by N/A% | -58.03 M Decreased by -269.17% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 17 | 0.00 Decreased by N/A% | -29.72 M Decreased by N/A% | Decreased by N/A% - |
| Dec 31, 16 | 0.00 Decreased by N/A% | -25.37 M Decreased by N/A% | Decreased by N/A% - |
| Sep 30, 16 | 0.00 Decreased by N/A% | -21.08 M Decreased by N/A% | Decreased by N/A% - |
| Jun 30, 16 | 0.00 Decreased by N/A% | -15.72 M Decreased by N/A% | Decreased by N/A% - |